Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
To analyze the relationship between the cellular composition of peripheral blood allografts and clinical outcome, we performed a prospective study in 45 adult patients who underwent allogeneic peripheral blood hematopoietic stem cell transplantation (HSCT) from a histocompatibility leukocyte antigen identical sibling donor for different hematological malignancies. The dose of CD34+, CD3+, CD4+, CD8+, and CD19+ lymphocytes, natural killer (NK) cells, natural killer T (NKT) cells, type 1 and type 2 dendritic cells (DC1 and DC2), as well as regulatory T (Treg) lymphocytes was analyzed. All patients were conditioned with busulphan and cyclophosphamide (BuCy2) +/- VP-16 and received a short course of methotrexate and cyclosporin-A as graft-versus-host disease (GVHD) prophylaxis. Acute GVHD (aGVHD) was present in 9 of 43 (21%) patients, and chronic GVHD (cGVHD) developed in 18 of 39 (46%) patients. There was a significantly higher incidence of aGVHD in patients receiving more than 6x10(6)/kg CD34+ cells. In univariate analysis, variables associated with better survival were as follows: a dose of less than 1.5x10(7)/kg NKT cells and less than 1.7x10(6)/kg DC2 for disease-free survival (DFS), and a dose of less than 3x10(7)/kg NK cells, less than 1.5x10(7)/kg NKT cells, less than 3x10(6)/kg DC1, and less than 1.7x10(6)/kg DC2 for overall survival (OS). In the Cox regression analysis, the dose of NKT cells was the only variable associated with better DFS, while the doses of NK, NKT, and CD34+ cells (less than 8x10(6)/kg) were associated with better OS. In conclusion, different circulating cell populations, other than CD34+ cells, are also of relevance in predicting the clinical outcome after allogeneic peripheral blood HSCT.
Vela-Ojeda
J
J
Hematology Department, Stem Cell Transplant Program, Unidad Medica de Alta Especialidad Antonio Fraga Mouret National Medical Center La Raza, Instituto Mexicano del Seguro Social, México, DF, México. velaj12x@prodigy.net.mx
García-Ruiz Esparza
M A
MA
Reyes-Maldonado
E
E
Jiménez-Zamudio
L
L
García-Latorre
E
E
Moreno-Lafont
M
M
Estrada-García
I
I
Montiel-Cervantes
L
L
Tripp-Villanueva
F
F
Ayala-Sánchez
M
M
García-León
L D
LD
Borbolla-Escoboza
J R
JR
Mayani
H
H
D000293:Adolescent; D000328:Adult; D018941:Antigens, CD19 / Q000096:biosynthesis; D018952:Antigens, CD34 / Q000096:biosynthesis; D017252:CD3 Complex / Q000096:biosynthesis; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D002648:Child; D003713:Dendritic Cells / Q000378:metabolism*; D005260:Female; D006086:Graft vs Host Disease / Q000628:therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism*; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D007694:Killer Cells, Natural / Q000166:cytology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D050378:T-Lymphocytes, Regulatory / Q000378:metabolism; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous
D018941:Antigens, CD19; D018952:Antigens, CD34; D017252:CD3 Complex; D016179:Granulocyte Colony-Stimulating Factor